

# Genotypic Patterns of Multidrug-Resistant *Acinetobacter baumannii*: A Systematic Review

Golnar Rahimzadeh, Mohammad S. Rezai, Fereshteh Farshidi

Pediatric Infectious Diseases Research Center, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran

## Abstract

*Acinetobacter baumannii* (*A. baumannii*) is one of the most common bacteria in nosocomial infections. Inappropriate usage of antibiotics has led to expanding emergence resistance to *A. baumannii* as a multidrug-resistant (MDR) strain. Empirical antibiotic therapy is necessary to evaluate the resistant gene pattern of MDR *A. baumannii*. For this purpose, the present study evaluated the resistance genes pattern of MDR *A. baumannii* collected from hospitalized patients using a genotypic diagnostic technique. To find evidence related to the study objectives, databases were searched such as Google Scholar, Web of Science, Science Direct, PubMed, and Scopus from 2000 to 2022, with specified keywords in the title and text of the articles. Articles were included based on inclusion and exclusion criteria. The mentioned database displayed 284 articles. After screening, 65 eligible articles were included. The results showed that various b-lactamases genes, aminoglycoside-modifying enzymes (AMEs) genes, and pump-expressing genes are resistance gene patterns in MDR *A. baumannii* isolates. MDR *A. baumannii* has significantly become resistant to b-lactams, carbapenems, and aminoglycosides.

**Keywords:** *Acinetobacter baumannii*, molecular diagnostic, multidrug-resistant, systematic review

**Address for correspondence:** Prof. Mohammad S. Rezai, Pediatric Infectious Diseases Research Center, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari - 4815838477, Iran.

E-mail: rezai@mazums.ac.ir

**Submitted:** 19-Dec-2022; **Revised:** 30-Jan-2023; **Accepted:** 01-Feb-2023; **Published:** 21-Mar-2023

## INTRODUCTION

*Acinetobacter baumannii* (*A. baumannii*) is one of the most common bacteria in nosocomial infections, which causes many infections including skin and soft tissues, wound infections, bacteremia, endocarditis, urinary tract infections (UTIs), meningitis, and pneumonia. The mortality rate of ventilator-associated pneumonia (VAP) and infected blood caused by *A. baumannii* are reported from 40% to 70% and 28% to 43%, respectively.<sup>[1,2]</sup>

Currently, *A. baumannii* has been recognized as a multidrug-resistant (MDR) strain. According to the guidelines, MDR strains are known to be resistant to more than two different antibiotic classes containing carbapenems, aminoglycosides, ampicillin-sulbactam, cephalosporins, and fluoroquinolones. The principal mechanisms of resistance are

membrane alterations, overexpression of efflux pumps, overexpression of antibiotic-modifying enzymes, and modifications of target sites for antimicrobial agents.<sup>[3]</sup>

B-lactamases have made *A. baumannii* resistant to b-lactam antibiotics.<sup>[3]</sup> Carbapenems were recommended as the most effective drug for the treatment of *A. baumannii* infections.<sup>[3,4]</sup> However, this strain acquired metallo-beta-lactamases (MBLs), and oxacilinases, and has limited the effectiveness of this drug.<sup>[5]</sup> Furthermore, the emergence of colistin-resistant *A. baumannii* (Col-R-Ab) strain is reported. This resistance occurs due to changes in the structure of the lipopolysaccharide (LPS) and the presence of plasmid-carrying genes (*mcr-1*, *mcr-2*, *mcr-3*, and *mcr-4.3*).<sup>[3]</sup>

The prevalence of antibiotic resistance and experimental prescription of antibiotics has increased without knowing

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

**For reprints contact:** WKHLRPMedknow\_reprints@wolterskluwer.com

**How to cite this article:** Rahimzadeh G, Rezai MS, Farshidi F. Genotypic patterns of multidrug-resistant *Acinetobacter baumannii*: A systematic review. *Adv Biomed Res* 2023;12:56.

### Access this article online

Quick Response Code:



Website:  
www.advbiores.net

DOI:  
10.4103/abr.abr\_434\_22

the antibiotic resistance genes pattern in various countries.<sup>[6]</sup> To detect the antibiotic resistance gene patterns in various countries and choose the correct antibiotics, screening the antibiotic resistance genes pattern of MDR *A. baumannii* over time may provide valuable data.

During the past two decades, molecular approaches have been introduced as a valuable technique to detect antibiotic resistance gene patterns in MDR *A. baumannii* isolates.<sup>[7-14]</sup> For this purpose, this study is to evaluate the antibiotic resistance gene patterns of MDR *A. baumannii* isolates using a genotypic diagnostic technique.

## MATERIALS AND METHODS

To find evidence related to the study purpose objectives, databases such as Google Scholar, Web of Science, Science Direct, PubMed, and Scopus were searched from 2000 to 2022, with keywords specified in the title and text of the articles. The specified keywords for searching English language databases included “MDR *A. baumannii*,” “PCR,” “RT PCR,” “multiplex PCR,” “b-lactamases,” “efflux pumps,” and “aminoglycoside-modifying enzymes,” which were used by the MeSH strategy.

The inclusion criteria included studies published in English, genotypic diagnostic techniques, and MDR *A. baumannii* isolates. The exclusion criteria included studies published in Persian, articles that were presented at national and international congresses, letters to editors, review articles, and phenotypic diagnostic techniques.

Finally, studies were identified and reviewed after excluding duplicates during primary screening. In the secondary screening, the full text of the articles was evaluated [Figure 1]. Data were extracted and recorded, including first author, duration isolation of MDR *A. baumannii*, country, number of samples, resistant gene patterns, and genotypic diagnostic technique, resistance to antibiotics [Table 1].

## RESULTS

The mentioned databases displayed 284 articles. After the exclusion of duplicate articles, 268 articles were reviewed. Finally, 65 articles were selected based on the exclusion and inclusion criteria [Figure 1]. The results showed different classes or subclasses of b-lactamases, AMEs, and efflux pumps genes were isolated from MDR *A. baumannii* isolates from the wound, blood, urine, catheter tips, soft tissue, bronchial aspirates, sputum, vascular catheter, stool, and cerebrospinal fluid (CSF).

## DISCUSSION

This study systematically reviewed 65 published English studies in various countries from 2000 to 2022 and evaluated the antibiotic resistance gene pattern of MDR *A. baumannii*, which were isolated from the wound, blood, urine, catheter tips, soft tissue, bronchial aspirates, sputum, vascular catheter, stool, and CSF. Out of 65 studies, 55 studies showed resistance to b-lactams, aminoglycosides, and fluoroquinolones.

Resistance to b-lactams can due to the expression of oxacillinases, MBLs, b-lactamases genes. Higgins *et al.*,<sup>[20,21]</sup> and other studies detected oxacillinases and MBLs such as *blaOXA-23*, *blaOXA-24*, *blaOXA-51*, *blaOXA-58*, *blaOXA-143*, *bla IMP*, *blaVIM*, *bla GIM*, *bla SMP*, and *bla NDM* in MDR *A. baumannii*.<sup>[15-49,51-55,68-77,79]</sup>

Oxacillinases significantly hydrolyze some antibiotics belonging to cephalosporins such as methicillin and amoxicillin. They are part of the epidemiological problem of the resistant *A. baumannii* strains. Its expression considerably increases the resistance to carbapenems and cephalosporins.<sup>[9,10]</sup> *blaOXA-58* confers the antibiotics resistance mechanism to penicillin, imipenem, and oxacillin, whereas it cannot hydrolysis expanded-spectrum cephalosporins<sup>[11]</sup> *blaOXA-23*-like hydrolyze ticarcillin, meropenem, amoxicillin, and imipenem.<sup>[12]</sup> In the study by Higgins and other studies, the *blaOXA-23* gene was detected in MDR *A. baumannii*.<sup>[20-24,27,34,35,37,38,40,43,45,49,52,54,68,69,73,76,79]</sup>




Figure 1: Flowchart of study selection

**Table 1: Information of studies selection**

References	No	First author	Duration of isolation	Country	No. Sa	Samples	Resistant genes pattern	PCR	Multiplex PCR	RT-PCR	Resistance to antibiotics
[15]	1	Jeong <i>et al.</i>	2005	Korea	10	respiratory secretions	PER-1, PER-2	■			carbapenems, b-lactams, aminoglycosides
[16]	2	Lee <i>et al.</i>	2003-2004	Korea	1234	sputum, urine	blaIMP-1, blaVIM-2	■			carbapenems, b-lactams, aminoglycosides
[17]	3	Hujer <i>et al.</i>	2005	Atlanta	800		AmpC b-lactamases, blaADC-7	■			ampicillin, piperacillin, cephalothin, Cefazidime, cefepime, cefoxitin, cefotaxime, carbapenems, b-lactams, aminoglycosides
[18]	4	Jeon <i>et al.</i>	2002-2006	Korea	48	blood	blaADC-68	■			carbapenems, b-lactams, aminoglycosides
[19]	5	Bou <i>et al.</i>	2000	Spain	23	bronchial aspirate	bla OXA-24				carbapenems, b-lactams, aminoglycosides
[20]	6	Higgins <i>et al.</i>	2004	Brazil	3	blood	blaOXA-23, blaOXA-40, blaOXA58, bla IMP, VPM, GIM, SPM, SIM	■			carbapenems, b-lactams, aminoglycosides
[21]	7	Higgins <i>et al.</i>	2013	USA, Mexico	10	wound, blood, sputum, tracheal secretion	blaOXA-23, blaOXA-24, blaOXA-51, blaOXA-58, blaOXA-143, bla IMP, blaVIM, blaGIM, blaSPM, blaSIM, blaNDM, blaOXA235, blaOXA236, blaOXA237	■	■		carbapenems, b-lactams, aminoglycosides
[22]	8	Huang <i>et al.</i>	2012	Iraq	57	wound	blaOXA-23, blaOXA-24/40, blaOXA-51, blaOXA-58		■		carbapenems, b-lactams, aminoglycosides
[23]	9	Poirel <i>et al.</i>	2003	France	13	skin burn infection	blaOXA-58	■			penicillin, Oxacillin, Imipenem, aminoglycosides
[24]	10	Adams <i>et al.</i>	2008	New York	6	blood	blaTEM-1, blaVEB-1, AmpC, blaOXA-69, blaOXA-23, blaOXA-10, blaOXA-51, blaOXA-66, blaOXA-20, blaOXA-75, blaOXA-58, tetA, cat, cmlA; sulI, dhfrX	■			ampicillin, ampicillin-sulbactam, ceftazolin, Imipenem, cefepime, meropenem, azteronam, gentamicin, amikacin, tigecyclin, ciprofloxacin, Trimethoprim-sulfamethoxazole
[25]	11	Bogaerts <i>et al.</i>	2008-2009	Belgium	125	wounds, abscesses, endotracheal aspirates, pleural fluid, blood	GES-11, GES-1, GES-14	■	■		ampicillin, ampicillin-sulbactam, ceftazolin, Imipenem, cefepime, meropenem, azteronam, gentamicin, amikacin, tigecyclin, ciprofloxacin, Trimethoprim-sulfamethoxazole
[26]	12	Bonnin <i>et al.</i>	2010	France	1	bronchial lavage	bla PER-1, bla PER-7, OXA-23, blaTEM, blaSHV, blaPER-1, blaVEB-1, blaGES-1, and blaCTX-M, blaampC, blaIMP, blaVIM, blaSIM, blaNDM	■			ampicillin, ampicillin-sulbactam, ceftazolin, Imipenem, cefepime, meropenem, azteronam, gentamicin, amikacin, tigecyclin, ciprofloxacin, Trimethoprim-sulfamethoxazole
[27]	13	Brown <i>et al.</i>	1993-1994	Argentina	6	BAL, bronchial alveolar lavage	blaOXA-51, blaOXA-23, blaOXA-24	■			amoxicillin, co-amoxiclav, cephaloridine, cefotaxim, Imipenem, gentamicin, meropenem, sulbactam

*Contd...*

**Table 1: Contd...**

References	No	First author	Duration of isolation	Country	No. Sa	Samples	Resistant genes pattern	PCR	Multiplex PCR	RT. PCR	Resistance to antibiotics
[28]	14	Chu <i>et al.</i>	1994-1998	Hong Kong	97	wound, blood	blaIMP11, blaIMP12, blaIMP4	■			aztreonam, piperacillin, piperacillin-tazobactam, cefotaxim, Imipenem, gentamicin, meropenem, sulbactam
[29]	15	Dhabaan <i>et al.</i>	2015	Malaysia	1	blood	piIN, piIV, piIT, piIQ, piIM, piIW, piIP, piIL, piIO, piIL, piIY			■	Carbapenems, aminoglycosides
[30]	16	Endimiani <i>et al.</i>	1999-2005	Italy	470	wound, blood, urine, Soft tissue, Vascular catheter, sputum	TEM, SHV, PER, VEB, CTX-M	■			Tobramycin, Cipfloxacin, piperacillin, Levofloxacin, Cefepime, Ceftriaxone, gentamicin, Cefazidime, Cefotaxime, Aztreonam
[31]	17	Gales <i>et al.</i>	2002	Brazil	1	tracheal secretion	TEM-4, SHV-1, SHV-3, SHV-4, SHV-5	■			Carbapenems, aminoglycosides
[32]	18	Hamidian <i>et al.</i>	2015	Sydney	1	wound	blaPER, aadB, aadA13/2, aadA2, strAB, sul1	■			neomycin, nalidixic acid, streptomycin, sulfamethoxazole, spectinomycin, trimethoprim
[33]	19	Sohrabi <i>et al.</i>	2008-2009	Iran	100	Sputum, E-tube, wound, urine, blood, catheter, bronchial washing, csf, abscesses	blaOXA-51, bla, OXA-23, blaOXA-40, bla OXA-58	■			ampicillin, ampicillin-sulbactam, piperacillin, piperacillin-tazobactam, cepha-lothim, cefoxitin, cefepazone, Cefazidime, cefotaxime, cefepime and aztreonam
[34]	20	Koh <i>et al.</i>	1996-2001	Singapore	114	various clinical sources	blaIMP-4, blaOXA-23	■			carbapenems, b-lactams, aminoglycosides
[35]	21	Sun <i>et al.</i>	2019	China	87	various clinical sources	blaOXA-23, Ade-B, int-1, ISCR-1			■	carbapenems, b-lactams, aminoglycosides
[36]	22	AlAmri <i>et al.</i>	2017-2018	Saudi Arabia	103	wound, blood, urine, catheter tips, soft tissue, bronchial aspirates sputum	OXA-51, OXA-23, NDM, VIM, KPC				Ceftazidime, piperacillin/tazobactam, cefepime, ciprofloxacin.
[37]	23	Genteluci <i>et al.</i>	2010-2011	Brazil	92	urine, blood, catheter, tracheal secretion, wound, broncho alveolar lavage	blaOXA-23, blaOXA-24, blaOXA-51, blaOXA-58, blaOXA-143	■			Carbapenem, meropenem, levofloxacin, trimethoprim
[38]	24	Raro <i>et al.</i>	2010	Brazil	858	gloves healthcare workers, hospital rooms, bronchial lavage, skin biopsy, sputum, urine	blaOXA-51, blaOXA-23	■			piperacillin/tazobactam, cefepime, ciprofloxacin. Carbapenem, meropenem, levofloxacin, trimethoprim
[39]	25	Reem <i>et al.</i>	2018-2019	Egypt	206	various clinical sources	blaOXA-51-like, OXA-23, blaNDM-1, blaSPM, blaVIM, blaSIM-1, bla KPC			■	Ceftazidime, piperacillin/tazobactam, cefepime, ciprofloxacin. Carbapenem, meropenem, levofloxacin, trimethoprim

*Contd...*

**Table 1: Contd...**

References	No	First author	Duration of isolation	Country	No. Sa	Samples	Resistant genes pattern	PCR	Multiplex PCR	RT-PCR	Resistance to antibiotics
[40]	26	Qureshi et al.	2007-2014	Pennsylvania	38	various clinical sources	blaOXA-51-like, blaOXA-23, blaOXA-40, blaOXA-58	■	■	■	colistin, piperacillin-tazobactam, gentamicin, Imipenem, meropenem, doripenem, ciprofloxacin, trimethoprim-sulfamethoxazole, tobramycin, amikacin, ampicillin-sulbactam
[41]	27	Goudarzi et al.	2018	Iran	128	various clinical sources	blaIMP, blaVIM, blaNDM	■	■	■	cefixime, piperacillin-tazobactam, gentamicin, Imipenem, doripenem, ertapenem, cefotaxime, ciprofloxacin, trimethoprim-sulfamethoxazole, tobramycin, amikacin, ampicillin-sulbactam, ceftazidime, carbapenems, b-lactams, aminoglycosides
[42]	28	Yang et al.	2010-2014	China	400	stool, Sputum	blaNDM, blaOXA-23-like, blaOXA-40-like, blaOXA-51-like, blaOXA-58-like	■	■	■	colistin, piperacillin-tazobactam, gentamicin, Imipenem, meropenem, gentamicin, doripenem, ciprofloxacin, trimethoprim-sulfamethoxazole, tobramycin, amikacin, ampicillin-sulbactam, ceftazidime, carbapenems, b-lactams, aminoglycosides
[43]	29	Yamamoto et al.	2004-2010	Japan	490	blood, urine, wound, sputum, nasal swab, bile juice, drainage tube	blaIMP, blaVIM, blaSIM, blaNDM-1, blaOXA-23-like, blaOXA-24-like, blaOXA-51-like, blaOXA-58-like, aacA4, aacC1, aacC2, aadB, aadA1, aphA1, aphA6	■	■	■	colistin, piperacillin-tazobactam, gentamicin, Imipenem, meropenem, gentamicin, doripenem, ciprofloxacin, trimethoprim-sulfamethoxazole, tobramycin, amikacin, ampicillin-sulbactam, tobramycin; gentamicin, Imipenem, meropenem, gentamicin, ciprofloxacin, amikacin, aztreonam, Cefepime, Cefazidime, Ceftriaxone
[44]	30	Vala et al.	2012	Iran	75	wound samples	IMP, VIM, SPM, GIM, OXA-48, BIC, NDM, DIM, KPC	■	■	■	cefixime, aztreonam, gentamicin, Imipenem, Cefazidime, meropenem, cefotaxime, ciprofloxacin, piperacillin, ampicillin/sulbactam, piperacillin/tazobactam, ofloxacin, ciprofloxacin, amikacin, gentamicin
[45]	31	Tsakris et al.	2004-2005	Greece	5	blood, urine, CSF, bronchial fluid	blaIMP, blaVIM, blaSPM, blaOXA-23-like, blaOXA-24-like, blaOXA-58-like, blaOXA-51-like	■	■	■	Carbapenems, b-lactams, aminoglycosides
[46]	32	Brown et al.	1996-2000	Argentina, South Africa, Hong Kong, Spain, Singapore, Turkey	226	faecal samples	OXA-51	■	■	■	Carbapenems, b-lactams, aminoglycosides

Contd...

**Table 1: Contd...**

References	No	First author	Duration of isolation	Country	No. Sa	Samples	Resistant genes pattern	PCR	Multiplex PCR	RT. PCR	Resistance to antibiotics
[47]	33	Peymani <i>et al.</i>	2008-2009	Iran	100	rachea, urine, sputum, blood, catheter, bronchial washings, wound, ascite fluid, abscess drainage, cerebrospinal fluid	Int1, Int2	■			cefipime, aztreonam, gentamicin, Imipenem, Cefazidime, meropenem, cefotaxime, ciprofloxacin, piperacillin/ampicillin/sulbactam, piperacillin/tazobactam, ofloxacin, ciprofloxacin, amikacin, gentamicin, aztreonam, Levofloxacin, Ticarcillin-clavulanic acid
[48]	34	Nemeec, <i>et al.</i>	1991-2001	Belgium, Bulgaria, Denmark, Spain, France, Greece, Italy, Netherlands, Poland, Portugal	106	various clinical sources	aacCI, aphA1, aphA6, aadB, aacA4	■			cefipime, aztreonam, gentamicin, Imipenem, Cefazidime, meropenem, cefotaxime, ciprofloxacin, piperacillin, ampicillin/sulbactam, piperacillin/tazobactam, ofloxacin, ciprofloxacin, amikacin, gentamicin, aztreonam, Levofloxacin, Ticarcillin-clavulanic acid, azteronam
[49]	35	Peymani, <i>et al.</i>	2008-2009	Iran	100	Sputum, E-tube, wound, urine, blood, catheter, bronchial washing, csf, abscesses	BlaIMP, blaVIM	■			amikacin, gentamicin, tetracycline, tobramycin, ampicillin, piperacillin, piperacillin-tazobactam, cephalothin, ceftoxitin, cefoperazone, Cefazidime, cefotaxime, cefepime, aztreonam, Imipenem
[50]	36	Yoon, <i>et al.</i>	2011	France	14	various clinical sources	AdeABC, AdeFGH, AdeIJK	■		■	cefipime, aztreonam, gentamicin, Imipenem, Cefazidime, meropenem, cefotaxime, ciprofloxacin, piperacillin/ampicillin/sulbactam, piperacillin/tazobactam, ofloxacin, ciprofloxacin, amikacin, gentamicin, aztreonam, Levofloxacin, Ticarcillin-clavulanic acid, tetraacycline
[51]	37	Khaledi, <i>et al.</i>	2011-2012		100	various clinical sources	abaye1582001, abaye002647, abaye 2281468	■	■	■	cefipime, aztreonam, gentamicin, Imipenem, Cefazidime, meropenem, cefotaxime, ciprofloxacin, piperacillin, ampicillin/sulbactam, piperacillin/tazobactam, ofloxacin, ciprofloxacin, amikacin, gentamicin, aztreonam, Levofloxacin, Ticarcillin-clavulanic acid, tetraacycline

*Contd...*

**Table 1: Contd...**

References	No	First author	Duration of isolation	Country	No. Sa	Samples	Resistant genes pattern	PCR	Multiplex PCR	RT-PCR	Resistance to antibiotics
[52]	38	Merkier, <i>et al.</i>	1982-2005	Buenos Aires	200	various clinical sources	blaOXA-24,25,26,40, blaIMP-1,4,5,6,7,9,10,16,18,21, blaVIM-1,2,3,4,5,11,8, blaOXA-23,27,49, 58 blaVEB-1	■			Carbapenems, aminoglycosides
[53]	39	Naas, <i>et al.</i>	2003	France	290	Blood, catheters, urine, respiratory tract, skin, wounds		■			cefipime, aztreonam, gentamicin, Imipenem, Cefazidime, meropenem, cefotaxime, ciprofloxacin, piperacillin, ampicillin/sulbactam, piperacillin/tazobactam, ofloxacin, ciprofloxacin, amikacin, gentamicin, aztreonam, Levofloxacin, Ticarcillin-clavulanic acid, tetracycline
[54]	40	Shahcheraghi, <i>et al.</i>	2009-2010	Iran	2300	blood, wound, urine, sputum, respiratory tract	blaVIM-2, blaSPM-1, blaIMP-2, blaGES-1, blaOXA-51, blaOXA-23	■			cefipime, aztreonam, gentamicin, Imipenem, Cefazidime, meropenem, cefotaxime, ciprofloxacin, piperacillin, ampicillin/sulbactam, piperacillin/tazobactam, ofloxacin, ciprofloxacin, amikacin, gentamicin, aztreonam, Levofloxacin, Ticarcillin-clavulanic acid, tetracycline
[55]	41	Yum, <i>et al.</i>	1998-1999	Korea	28	various clinical sources	blaVIM-2, blaIMP-1	■			carbapenems, b-lactams, aminoglycosides
[56]	42	Beheshti, <i>et al.</i>	2010-2011	Iran	98	wound	adeSR, adeB 1	■			aminoglycosides, fluoroquinolones, β-lactams, chloramphenicol, trimethoprim, erythromycin and tetracycline
[57]	43	Ranjbar, <i>et al.</i>	2016	Iran	79	ulcer, urine, blood, sputum	adeA, adeB, adeC	■			aminoglycosides, fluoroquinolones, β-lactams, chloramphenicol, trimethoprim, erythromycin and tetracycline
[58]	44	Nogbou, <i>et al.</i>	2018-2020	Africa	103	various clinical sources	adeR, adeS, adeB			■	aminoglycosides, fluoroquinolones, β-lactams, chloramphenicol, trimethoprim, erythromycin and tetracycline
[59]	45	Mobasseri, <i>et al.</i>	2016-2017	Iran	51	various clinical sources	adeJ, abeM			■	cefipime, aztreonam, gentamicin, Imipenem, Cefazidime, meropenem, cefotaxime, ciprofloxacin, piperacillin, ampicillin/sulbactam, piperacillin/tazobactam, ofloxacin, ciprofloxacin, amikacin, gentamicin, aztreonam, Levofloxacin, Ticarcillin-clavulanic acid, tetracycline

*Contd...*

**Table 1: Contd...**

References	No	First author	Duration of isolation	Country	No. Sa	Samples	Resistant genes pattern	PCR	Multiplex PCR	RT. PCR	Resistance to antibiotics
[60]	46	Angoti, <i>et al.</i>	2013-2014	Iran	26	blood, wound, abscesses, urine, sputum, respiratory tract, fluid bodies	adeA, adeB, adeC, abeM	■		■	cefepime, aztreonam, gentamicin, Imipenem, Cefazidime, meropenem, cefotaxime, ciprofloxacin, piperacillin, ampicillin/sulbactam, piperacillin/tazobactam, ofloxacin, ciprofloxacin, amikacin, gentamicin, aztreonam, Levofloxacin, Ticarcillin-clavulanic acid, tetracycline
[61]	47	AlQumaizi, <i>et al.</i>	2021	India	30	blood, sterile body fluids (BF), cerebrospinal fluids	CarO porin, AdeB, AdeG, AdeI, AdeY, AbeM, oprD, carO	■		■	Tigecycline, ceftazidime, gentamicin, Imipenem, Cefazidime, meropenem, cefotaxime, ciprofloxacin, piperacillin, ampicillin/sulbactam, piperacillin/tazobactam, ofloxacin, ciprofloxacin, amikacin, gentamicin, aztreonam, Levofloxacin, Ticarcillin-clavulanic acid, tetracycline
[62]	48	Rafei, <i>et al.</i>	2019	Iran	70	pulmonary secretions	adeB, adeG, adeI, abeM	■		■	β-lactams, tetracycline, fluoroquinolones, chloramphenicol, trimethoprim, rifampin, fusidic acid, erythromycin, lincosamides, novobiocin, acridine, pyronine, safranin
[63]	49	Rajamohan, <i>et al.</i>	2005-2007	USA	86	various clinical sources	adeB, adel, qacE				β-lactams, tetracycline, fluoroquinolones, chloramphenicol, trimethoprim, rifampin, fusidic acid, erythromycin, lincosamides, novobiocin, acridine, pyronine, safranin
[64]	50	Tahbaz, <i>et al.</i>	2018	Iran	47	burn sample	ACC (6'), aph (3')-Via, aph (3')-IIb, aadA1, aphA1, aph 6			■	cefepime, aztreonam, gentamicin, Imipenem, Cefazidime, meropenem, cefotaxime, ciprofloxacin, piperacillin, ampicillin/sulbactam, piperacillin/tazobactam, ofloxacin, ciprofloxacin, amikacin, gentamicin, aztreonam, Levofloxacin, Ticarcillin-clavulanic acid, tetracycline, Amikacin, Gentamicin, Tobramycin

*Contd...*



**Table 1: Contd...**

References	No	First author	Duration of isolation	Country	No. Sa	Samples	Resistant genes pattern	PCR	Multiplex PCR	RT. PCR	Resistance to antibiotics
[65]	51	Asadollahi, <i>et al.</i>	2010	Iran	100	various clinical sources	aphA6, aacC1, aacC2, aacA4, aadB, aadA1,	■			amikacin, gentamicin, Imipenem, Cefazidime, meropenem, cefotaxime, ciprofloxacin, piperacillin, ampicillin/sulbactam, tazobactam, ofloxacin, ciprofloxacin, amikacin, gentamicin, aztreonam, Levofloxacin, Ticarcillin-clavulanic acid, tetracycline, Amikacin, Gentamicin, Tobramycin
[66]	52	Kishk, <i>et al.</i>	2019	Egypt	52	urine, sputum, blood, wound	aphA6, addA1, aacC1, aphA6	■			amikacin, gentamicin, Imipenem, Cefazidime, meropenem, cefotaxime, ciprofloxacin, piperacillin, ampicillin/sulbactam, piperacillin/tazobactam, ofloxacin, ciprofloxacin, amikacin, gentamicin, aztreonam, Levofloxacin, Ticarcillin-clavulanic acid, tetracycline, Amikacin, Gentamicin, Tobramycin
[67]	53	Rashvand, <i>et al.</i>	2016-2018	Iran	192	sputum, trachea, Broncho alveolar lavage, urine, blood, wounds	aph (30)-VI, aac (60)-Ib, aac (3)-II, aph (30)-Ia, armA	■			cefipime, aztreonam, gentamicin, Imipenem, Cefazidime, meropenem, cefotaxime, ciprofloxacin, piperacillin, ampicillin/sulbactam, piperacillin/tazobactam, ofloxacin, ciprofloxacin, amikacin, gentamicin, aztreonam, Levofloxacin, Ticarcillin-clavulanic acid, gentamicin, tobramycin, Levofloxacin
[68]	54	Hammoudi, <i>et al.</i>	2012	Egypt, Turkey, Spain, Italy	<i>n</i>	various clinical sources	bla <sub>oxa-23</sub> , bla <sub>oxa-24</sub> , bla <sub>oxa-40</sub> , bla <sub>oxa-58</sub> , bla <sub>KPC</sub> , bla <sub>GES</sub> , bla <sub>IMP-1</sub> , bla <sub>IMP-2</sub> , bla <sub>NDM</sub> , bla <sub>VIM</sub>	■			β-lactams, tetracycline, fluoroquinolones, chloramphenicol, trimethoprim, rifampin, fusidic acid, erythromycin, lincosamides, novobiocin, acridine, pryonine, tazobactam
[69]	55	Ghaith, <i>et al.</i>	2015	Egypt	50	Blood, urine	bla <sub>OXA-23</sub> -like, bla <sub>OXA-24</sub> -like, bla <sub>OXA-51</sub> -like, bla <sub>OXA-58</sub> -like		■		β-lactams, tetracyclines, cefepime, aztreonam, gentamicin, Imipenem, Cefazidime, meropenem, cefotaxime, ciprofloxacin, piperacillin, ampicillin/sulbactam, piperacillin

*Contd...*

**Table 1: Contd...**

References	No	First author	Duration of isolation	Country	No. Sa	Samples	Resistant genes pattern	PCR	Multiplex PCR	RT. PCR	Resistance to antibiotics
[70]	56	Khalilzadegan, <i>et al.</i>	2013	Iran	588	surface of ICUs	blaCTX, blaTEM		■		Imipenem, meropenem, ceftazoxime, oxacillin, ceftazidime, meropenem, gentamicin, lincomycin, ciprofloxacin, Cefazidime, cefotaxime, ampicillin, tetracycline, cefixime, colistin
[71]	57	lowe, <i>et al.</i>	2017	South Africa	150	various clinical sources	csuA, csuD				Imipenem, meropenem, ceftazoxime, oxacillin, ceftazidime, meropenem, gentamicin, trimethoprim/sulfamethoxazole
[72]	58	Mak, <i>et al.</i>	2006-2007	Australia	32	wound, catheter, blood, urine, bed railings, air-conditioning vents	SAbal, ISAbal, OXA-23-like, OXA-51-like, OXA-58-like, aacCl, orfX, orfX', aadAl		■		Cefepime, aztreonam, gentamicin, Imipenem, Cefazidime, meropenem, cefotaxime, ciprofloxacin, piperacillin, ampicillin/sulbactam, piperacillin/tazobactam, ofloxacin, ciprofloxacin, amikacin, gentamicin, aztreonam, Levofloxacin, Ticarcillin-clavulanic acid, tetracycline
[73]	59	Nojookambari, <i>et al.</i>	2019-2020	Iran	60	CSF, blood, urine, tracheal tube, central venous line, dialysis fluid, respiratory secretions	blaOXA-51-like, blaOXA-23-like, blaTEM, blaOXA-24-like, blaPER, blaSHV, blaCTX-M, blaOXA-58-like, blaIMP, ISAbal, ISAbal		■		Cefepime, aztreonam, gentamicin, Imipenem, Cefazidime, meropenem, cefotaxime, ciprofloxacin, piperacillin, ampicillin/sulbactam, piperacillin/tazobactam, ofloxacin, ciprofloxacin, amikacin, gentamicin, aztreonam, Levofloxacin, Ticarcillin-clavulanic acid, tetracycline
[74]	60	Rynga, <i>et al.</i>	2014	Delhi	100	Blood, Urine	IM, VIM, SIM, IMP		■		Cefepime, aztreonam, gentamicin, Imipenem, Cefazidime, meropenem, cefotaxime, ciprofloxacin, piperacillin, ampicillin/sulbactam, piperacillin/tazobactam, ofloxacin, ciprofloxacin, amikacin, gentamicin, aztreonam, Levofloxacin, Ticarcillin-clavulanic acid, tetracycline
[75]	61	Soltani, <i>et al.</i>	2015-2016	Iran	92	eye, blood, urine, blood, urine, respiratory, skin, soft tissue	bla, VIM, blaIMP, blaSPM, sul1, sul2		■		polymyxin B, ceftipime, aztreonam, gentamicin, Imipenem, Cefazidime, meropenem, cefotaxime, ciprofloxacin, piperacillin, ampicillin/sulbactam, piperacillin/tazobactam, ofloxacin, ciprofloxacin, amikacin, gentamicin, aztreonam, Levofloxacin, Ticarcillin-clavulanic acid, tetracycline

*Contd...*

**Table 1: Contd...**

References	No	First author	Duration of isolation	Country	No. Sa	Samples	Resistant genes pattern	PCR	Multiplex PCR	RT. PCR	Resistance to antibiotics
[76]	62	Uddin, <i>et al.</i>	2014-2015	Pakistan	7	tracheal aspirates, urine, blood, pus, stool	blaOXA-23, CTX-M, AmpCs	■			Cefepime, aztreonam, gentamicin, Imipenem, Ceftazidime, meropenem, cefotaxime, ciprofloxacin, piperacillin/ampicillin/sulbactam, piperacillin/tazobactam, ofloxacin, ciprofloxacin, amikacin, gentamicin, aztreonam, Levofloxacin, Ticarcillin-clavulanic acid, tetracycline
[77]	63	asaad, <i>et al.</i>	2018-2019	Egypt	94	blood, sputum	bap, ompA, blaPER-1	■			Cefepime, aztreonam, gentamicin, Imipenem, Ceftazidime, meropenem, cefotaxime, ciprofloxacin, piperacillin/ampicillin/sulbactam, piperacillin/tazobactam, ofloxacin, ciprofloxacin, amikacin, gentamicin, aztreonam, Levofloxacin, Ticarcillin-clavulanic acid, tetracycline
[78]	64	Behdad, <i>et al.</i>	2019	Iran	100	blood, sputum, trachea, wound	AdeIJK, AdeAC, AdeRS, AdeFH, AdeA, AdeC, AdeF, AdeH, AdeS, AdeR, AdeR, AdeI, AdeJ, AdeK			■	Cefepime, aztreonam, gentamicin, Imipenem, Ceftazidime, meropenem, cefotaxime, ciprofloxacin, piperacillin/ampicillin/sulbactam, piperacillin/tazobactam, ofloxacin, ciprofloxacin, amikacin, gentamicin, aztreonam
[79]	65	Ben, <i>et al.</i>	2013	Taiwan	213	blood, sputum, urine, pleural fluid, ascitic fluid, wounds	blaOXA-23, blaTEM-1, blaOXA-51,		■		Cefepime, aztreonam, gentamicin, Imipenem, Ceftazidime, meropenem, cefotaxime, ciprofloxacin, piperacillin/ampicillin/sulbactam, piperacillin/tazobactam, ofloxacin, ciprofloxacin, amikacin, gentamicin, aztreonam

The *blaOXA-40*-like weakly hydrolyzes cephalosporins and carbapenems such as imipenem and ceftazidime. This enzyme is resistant to tazobactam and sulbactam clavulanic acid.<sup>[13-14]</sup> Qureshi<sup>[40]</sup> and Hammoudi<sup>[68]</sup> reported *A. baumannii* isolates were resistant to b-lactams and tazobactam by detection of *blaOXA-40*-like.

In previous reports, the incidence rate of MDR *A. baumannii* was reported to be 74%.<sup>[80]</sup> The prevalence of MDR *A. baumannii* has increased from 50% in 2001–2007 to 74% in 2010–2015 in Iran. Reasons for such an increase are uncontrolled and overuse of antimicrobial agents, trade among nations, lack of surveillance of MDR strains, lack of use of sensitive techniques for MDR detection in clinical labs, and a rising number of patients with prolonged hospitalization.<sup>[81,82]</sup>

The antibiotic choice for treating MDR *A. baumannii* infections is restricted, and lipopeptides can be an alternative treatment option. Polymyxin B and colistin can be effective in the treatment of urinary tract infections, infected wounds, and blood infections. However, nephrotoxicity is a detriment to their utilization.<sup>[83,84]</sup> Previous studies showed a combination of imipenem with aminoglycosides, glycolcyclines, ampicillin, rifampicin, aztreonam, sulbactam, and lipopeptides can produce a synergistic effect against MDR *A. baumannii*.<sup>[85]</sup> Combination therapies can significantly enhance bactericidal activity from 8.4–26.4 to 60.3–86.7%. A previous meta-analysis reported combinations of colistin–glycopeptide and polymyxin–carbapenem to have synergistic effect for 70% of isolates with relatively low toxicity.<sup>[85]</sup>

Other mechanisms of enzymatic resistance include AME expression. Mak *et al.*<sup>[72]</sup> and other studies detected *aacCI*, *orfX*, *orfX'*, and *aadA1* genes in MDR *A. baumannii* isolates.<sup>[64-67]</sup>

In the present study, 10 studies showed that overexpression of an efflux system can be an efficient mechanism for drug resistance in *A. baumannii* isolates.<sup>[50,56-63,78]</sup> The corresponding structural efflux pump genes are part of plasmids, transposons, or resistance islands,<sup>[86]</sup> which MDR *A. baumannii* acquires in hospital units such as intensive care units (ICU) and burns units or from the environment. Efflux pumps with other antibiotic resistance mechanisms allow bacteria to reach high-level resistance; moreover, they weakly increase the MICs.<sup>[87]</sup> Five superfamilies of efflux systems are associated with drug resistance: ATP-binding cassette (ABC) transporters, small multidrug resistance (SMR), and multidrug and toxic compound extrusion (MATE) families, major facilitator superfamily (MFS), and the resistance-nodulation-cell division (RND) family, which are the most clinically relevant.<sup>[88]</sup>

Efflux pumps confer multidrug resistance to gram-negative bacteria. AdeABC is the first characterized RND system in *A. baumannii*. AdeABC extrudes aminoglycosides, b-lactams, fluoroquinolones, tetracycline, tigecycline, macrolides, chloramphenicol, and trimethoprim. Overexpression of AdeABC significantly causes higher-level carbapenem

resistance.<sup>[89]</sup> Beheshti *et al.*, and other studies reported resistance to the mentioned antibiotics and detected *adeA*, *adeB*, *adeC*, *adeJ*, and *abeM* genes.<sup>[56-60,62,78]</sup> AdeIJK is the second RND efflux system, which contributes to intrinsic resistance to b-lactams.<sup>[63]</sup>

According to data in Table 1, antibiotic resistance gene pattern in MDR isolates is different in various countries even in different hospitals in the same country. Antibiotic resistance gene pattern, through rapid genotypic diagnostics technique (PCR, RT-PCR), can avoid or reduce the risk of clinical response failure, guide antibiotic prescribing for MDR isolates, and reduce the socioeconomic burden associated with antibiotic-resistant infections in the community. Detection of antibiotic resistance gene patterns in various regions causes the development of a better understanding of the relationship between antibiotic prescribing levels and significant non-development of antibiotic resistance in the community. Although matrix-assisted laser desorption ionization-time of flight (MALDI-TOF), next-generation sequencing (NGS), and whole-genome sequencing (WGS) are rapid and new genotypic diagnostic techniques to detect MDR isolates, in the present study, we did not investigate these methods to detect antibiotic resistance genes pattern in MDR isolates.

## CONCLUSION

MDR *A. baumannii* isolates are about many times more likely to resist than other bacteria related to hospital infections. MDR *A. baumannii* has widely become resistant to b-lactam antibiotics. Significant resistance to oxacillins has become part of the epidemiological problem of MDR *A. baumannii* isolates.

## Acknowledgment

The authors would like to thank the Pediatric Infectious Diseases Research Center at Bou-Ali Sina hospital in Sari.

## Financial support and sponsorship

Nil.

## Conflicts of interest

There are no conflicts of interest.

## REFERENCES

- Garnacho-Montero J, Ortiz-Leyba C, Fernández-Hinojosa E, Aldabó-Pallás T, Cayuela A, Marquez-Vácaro JA, *et al.* *Acinetobacter baumannii* ventilator-associated pneumonia: Epidemiological and clinical findings. *Intensive Care Med* 2005;31:649-55.
- Rahimzadeh G, Rezaei MS. Detection extended-spectrum beta-lactamase- and carbapenemase-producing *Enterobacteriaceae* isolates from clinical samples; Narrative review. *J. Isfahan Med. Sch* 2022;40:743-58.
- Medina E, Pieper DH. Tackling threats and future problems of multidrug-resistant Bacteria. *Curr Top Microbiol Immunol* 2016;398:3-33.
- Poirel L, Nordmann P. Carbapenem resistance in *Acinetobacter baumannii*: Mechanisms and epidemiology. *Clin Microbiol Infect* 2006;12:826-36.
- Alkasaby NM, El Sayed Zaki M. Molecular study of *Acinetobacter baumannii* isolates for Metallo-beta-lactamases and extended-spectrum-beta-lactamases genes in intensive care

- unit, Mansoura University Hospital, Egypt. *Int J Microbiol* 2017;2017:3925868.
6. Gootz TD, Marra A. *Acinetobacter baumannii*: An emerging multidrug-resistant threat. *Expert Rev Anti-Infect Ther* 2008;6:309-25.
  7. Karaaslan A, Soysal A, Altinkanat Gelmez G, Kepenekli Kadayifci E, Soyletir G, Bakir M. Molecular characterization and risk factors for carbapenem-resistant gram-negative bacilli colonization in children: Emergence of NDM-producing *Acinetobacter baumannii* in a newborn intensive care unit in Turkey. *J Hosp Infect* 2016;92:67-72.
  8. Roschanski N, Fischer J, Guerra B, Roesler U. Development of a multiplex real-time PCR for the rapid detection of the predominant beta-lactamase genes CTX-M, SHV, TEM and CIT-type AmpCs in Enterobacteriaceae. *PLoS One* 2014;9:e100956.
  9. Kaitany K CJ, Klinger NV, June CM, Ramey ME, Bonomo RA, Powers RA, et al. Structures of the class D carbapenemases OXA-23 and OXA-146: Mechanistic basis of activity against carbapenems, extended-spectrum cephalosporins, and aztreonam. *Antimicrob Agents Chemother* 2013;57:4848-55.
  10. Corvec S, Poirel L, Naas T, Drugeon H, Nordmann P. Genetics and expression of the carbapenem-hydrolyzing oxacillinase gene blaOXA-23 in *Acinetobacter baumannii*. *Antimicrob Agents Chemother* 2007;51:1530-3.
  11. Turton JF, Ward ME, Woodford N, Kaufmann ME, Pike R, Livermore DM, et al. The role of IS Abal in expression of OXA carbapenemase genes in *Acinetobacter baumannii*. *FEMS Microbiol Lett* 2006;258:72-7.
  12. Héritier C, Poirel L, Lambert T, Nordmann P. Contribution of acquired carbapenem-hydrolyzing oxacillinases to carbapenem resistance in *Acinetobacter baumannii*. *Antimicrob Agents Chemother* 2005;49:3198-202.
  13. Povilonis J, Seputiene V, Krasauskas R, Juskaite R, Miskinyte M, Suziedelis K, et al. Spread of carbapenem-resistant *Acinetobacter baumannii* carrying a plasmid with two genes encoding OXA-72 carbapenemase in Lithuanian hospitals. *J Antimicrob Chemother* 2013;68:1000-6.
  14. Bush K, Jacoby GA. Updated functional classification of beta-lactamases. *Antimicrob Agents Chemother* 2010;54:969-76.
  15. Jeong SH, Bae IK, Kwon SB, Lee K, Yong D, Woo GJ, et al. Investigation of a nosocomial outbreak of *Acinetobacter baumannii* producing PER-1 extended-spectrum  $\beta$ -lactamase in an intensive care unit. *J Hosp Infect* 2005;59:242-8.
  16. Lee K, Yum JH, Yong D, Lee HM, Kim HD, Docquier JD, et al. Novel acquired metallo- $\beta$ -lactamase gene, blaSIM-1, in a Class I integron from *Acinetobacter baumannii* clinical isolates from Korea. *Antimicrob Agents Chemother* 2005;49:4485-91.
  17. Hujer KM, Hamza NS, Hujer AM, Perez F, Helfand MS, Bethel CR, et al. Identification of a new allelic variant of the *Acinetobacter baumannii* cephalosporinase, ADC-7  $\beta$ -lactamase: Defining a unique family of class C enzymes. *Antimicrob Agents Chemother* 2005;49:2941-8.
  18. Jeon JH, Hong MK, Lee JH, Lee JJ, Park KS, Karim AM, et al. Structure of ADC-68, a novel carbapenem hydrolyzing class C extended-spectrum  $\beta$ -lactamase isolated from *Acinetobacter baumannii*. *Acta Crystallogr D Biol Crystallogr* 2014;70:2924-36.
  19. Bou G, Martínez-Beltrán J. Cloning, nucleotide sequencing, and analysis of the gene encoding an AmpC  $\beta$ -lactamase in *Acinetobacter baumannii*. *Antimicrob Agents Chemother* 2000;44:428-32.
  20. Higgins PG, Poirel L, Lehmann M, Nordmann P, Seifert H. OXA-143, a Novel Carbapenem-hydrolyzing class D  $\beta$ -lactamase in *Acinetobacter baumannii*. *Antimicrob Agents Chemother* 2009;53:5035-8.
  21. Higgins PG, Pérez-Llarena FJ, Zander E, Fernández A, Bou G, Seifert H. OXA-235, a novel class D  $\beta$ -lactamase involved in resistance to carbapenems in *Acinetobacter baumannii*. *Antimicrob Agents Chemother* 2013;57:2121-6.
  22. Huang XZ, Cash DM, Chahine MA, Nikolich MP, Craft DW. Development and validation of a multiplex TaqManReal-time PCR for rapid detection of genes encoding four types of class D carbapenemase in *Acinetobacter baumannii*. *J Med Microbiol* 2012;61:1532-7.
  23. Poirel L, Menuteau O, Agoli N, Cattoen C, Nordmann P. Outbreak of extended-spectrum  $\beta$ -lactamase VEB-1-producing isolates of *Acinetobacter baumannii* in a French hospital. *J Clin Microbiol* 2003;41:3542-7.
  24. Adams MD, Goglin K, Molyneux N, Hujer KM, Lavender H, Jamison JJ, et al. Comparative genome sequence analysis of multidrug-resistant *Acinetobacter baumannii*. *J Bacteriol* 2008;190:8053-64.
  25. Bogaerts P, Naas T, El Garch F, Cuzon G, Deplano A, Delaire T, et al. GES extended-spectrum  $\beta$ -lactamases in *Acinetobacter baumannii* isolates in Belgium. *Antimicrob Agents Chemother* 2010;54:4872-8.
  26. Bonnin RA, Nordmann P, Potron A, Lecuyer H, Zahar JR, Poirel L. Carbapenem-hydrolyzing GES-type extended-spectrum  $\beta$ -lactamase in *Acinetobacter baumannii*. *Antimicrob Agents Chemother* 2011;55:349-54.
  27. Brown S, Young HK, Amyes SGB. Characterisation of OXA-51, a novel class D carbapenemase found in genetically unrelated clinical strains of *Acinetobacter baumannii* from Argentina. *Clin Microbiol Infect* 2005;11:15-23.
  28. Chu YW, Afzal-Shah M, Houang ET, Palepou MI, Lyon DJ, Woodford N, et al. IMP-4, a novel metallo- $\beta$ -lactamase from nosocomial *Acinetobacter* spp. collected in Hong Kong between 1994 and 1998. *Antimicrob Agents Chemother* 2001;45:710-4.
  29. Dhabaan GN, AbuBakar S, Cerqueira GM, Al-Haroni M, Pang SP, Hassan H. Imipenem treatment induces expression of important genes and phenotypes in a resistant *Acinetobacter baumannii* isolate. *Antimicrob Agents Chemother* 2016;60:1370-6.
  30. Endimiani A, Luzzaro F, Migliavacca R, Mantengoli E, Hujer AM, Hujer KM, et al. Spread in an Italian hospital of a clonal *Acinetobacter baumannii* strain producing the TEM-92 extended-spectrum  $\beta$ -lactamase. *Antimicrob Agents Chemother* 2007;51:2211-4.
  31. Gales AC, Tognim MC, Reis AO, Jones RN, Sader HS. Emergence of an IMP-like metallo-enzyme in an *Acinetobacter baumannii* clinical strain from a Brazilian teaching hospital. *Diagn Microbiol Infect Dis* 2003;45:77-9.
  32. Hamidian M, Holt KE, Hall RM. Genomic Resistance Island AGI1 carrying a complex class I integron in a multiply antibiotic-resistant ST25 *Acinetobacter baumannii* isolate. *J Antimicrob Chemother* 2015;70:2519-23.
  33. Sohrabi N, Farajnia S, Akhi MT, Nahaei MR, Naghili B, Peymani A, et al. Prevalence of OXA-Type  $\beta$ -lactamases among *Acinetobacter baumannii* isolates from Northwest of Iran. *Microb Drug Resist* 2012;18:385-9.
  34. Koh TH, Sng LH, Wang GCY, Hsu LY, Zhao Y. IMP-4 and OXA  $\beta$ -lactamases in *Acinetobacter baumannii* from Singapore. *J Antimicrob Chemother* 2007;59:627-32.
  35. Sun H, Xiao G, Zhang J, Pan Z, Chen Y, Xiong F. Rapid simultaneous detection of bla<sub>oxa</sub>-23, Ade-B, int-1, and ISCR-1 in multidrug-resistant *Acinetobacter baumannii* using single-tube multiplex PCR and high resolution melting assay. *Infect Drug Resist* 2019;12:1573-81.
  36. AlAmri AM, AlQurayan AM, Sebastian T, AlNimr AM. Molecular surveillance of multidrug-resistant *Acinetobacter baumannii*. *Curr Microbiol* 2020;77:335-42.
  37. Genteluci GL, Gomes DBC, Pereira D, Neves MC, de Souza MJ, Rangel K, et al. Multidrug-resistant *Acinetobacter baumannii*: Differential adherence to HEp-2 and A-549 cells. *Braz J Microbiol* 2020;51:657-64.
  38. Raro OHF, Gallo SW, Ferreira CAS, Oliveira SD. Carbapenem-resistant *Acinetobacter baumannii* contamination in an intensive care unit. *Rev Soc Bras Med Trop* 2017;50:167-72.
  39. Hassan R, Tantawy M, Gouda NA, Elzayat MG, Gabra S, Nabih A, et al. Genotypic characterization of multiple drug resistant *Escherichia coli* isolates from a pediatric cancer hospital in Egypt. *Sci Rep* 2020;10:4165.
  40. Qureshi ZA, Paterson DL, Peleg AY, Adams-Haduch JM, Shutt KA, Pakstis DL, et al. Clinical characteristics of bacteremia due to extended-spectrum  $\beta$ -lactamase (ESBL)-producing *Enterobacteriaceae* in the era of CTX-M and KPC-type  $\beta$ -lactamases. *Clin Microbiol Infect* 2012;18:887-93.
  41. Goudarzi M, Fazeli M, Eslami G, Pouriran R, Hajikhani B, Dadashi M. Genetic diversity analysis of methicillin-resistant *Staphylococcus aureus* strains isolated from intensive care unit in Iran. *Oman Med J* 2019;34:118-25.
  42. Yang Q, Rui Y. Two multiplex real-time PCR assays to detect and differentiate *Acinetobacter baumannii* and non-*baumannii*

- Acinetobacter* spp. Carrying blaNDM, blaOXA-23-Like, blaOXA-40-Like, blaOXA-51-Like, and blaOXA-58-Like Genes. *PLoS One* 2016;11:e0158958.
43. Yamamoto M, Nagao M, Matsumura Y, Matsushima A, Ito Y, Takakura S, et al. Interspecies dissemination of a novel class I integron carrying blaIMP-19 among *Acinetobacter* species in Japan. *J Antimicrob Chemother* 2011;66:2480-3.
  44. Hakemi Vala M, Hallajzadeh M, Hashemi A, Goudarzi H, Tarhani M, Sattarzadeh Tabrizi M, et al. Detection of Ambler class A, B and D  $\beta$ -lactamases among *Pseudomonas aeruginosa* and *Acinetobacter baumannii* clinical isolates from burn patients. *Ann Burns Fire Disasters* 2014;27:8-13.
  45. Tsakris A, Ikonomidis A, Pournaras S, Tzouveleki LS, Sofianou D, Legakis NJ, et al. VIM-1 metallo- $\beta$ -lactamase in *Acinetobacter baumannii*. *Emerg Infect Dis* 2006;12:981-3.
  46. Brown S, Amyes SGB. The sequences of seven class D  $\beta$ -lactamases isolated from carbapenem-resistant *Acinetobacter baumannii* from four continents. *Clin Microbiol Infect* 2005;11:326-9.
  47. Peymani A, Farajnia S, Nahaei MR, Sohrabi N, Abbasi L, Ansarin K, et al. Prevalence of class I integron among multidrug-resistant *Acinetobacter baumannii* in Tabriz, northwest of Iran. *Pol J Microbiol* 2012;61:57-60.
  48. Nemeč A, Dolžani L, Brisse S, van den Broek P, Dijkshoorn L. Diversity of aminoglycoside-resistance genes and their association with class I integrons among strains of Pan-European *Acinetobacter baumannii* clones. *J Med Microbiol* 2004;53:1233-40.
  49. Peymani A, Nahaei MR, Farajnia S, Hasani A, Mirsalehian A, Sohrabi N, et al. High prevalence of metallo- $\beta$ -lactamase-producing *Acinetobacter baumannii* in a teaching hospital in Tabriz, Iran. *Jpn J Infect Dis* 2011;64:69-71.
  50. Yoon EJ, Balloy V, Fiette L, Chignard M, Courvalin P, Grillot-Courvalin C. Contribution of the Ade Resistance-Nodulation-Cell Division-Type Efflux Pumps to Fitness and Pathogenesis of *Acinetobacter baumannii*. *mBio* 2016;7:e00697-16.
  51. Khaledi A, Esmaili D, Jamehdar SA, Esmaili SA, Neshani A, Bahador A. Expression of MFS efflux pumps among multidrug resistant *Acinetobacter baumannii* clinical isolates. *Der Pharmacia Lettre* 2016;8:262-7.
  52. Merquier AK, Centrón D. blaOXA-51-type  $\beta$ -lactamase genes are ubiquitous and vary within a strain in *Acinetobacter baumannii*. *Int J Antimicrob Agents* 2006;28:110-3.
  53. Naas T, Coignard B, Carbone A, Blanckaert K, Bajolet O, Bernet C, et al. VEB-1 extended-spectrum  $\beta$ -lactamase-producing *Acinetobacter baumannii*, France. *Emerg Infect Dis* 2006;12:1214-22.
  54. Shahcheraghi F, Abbasalipour M, Feizabadi M, Ebrahimipour G, Akbari N. Isolation and genetic characterization of metallo- $\beta$ -lactamase and carbapenemase producing strains of *Acinetobacter baumannii* from patients at Tehran hospitals. *Iran J Microbiol* 2011;3:68-74.
  55. Yum JH, Yi K, Lee H, Yong D, Lee K, Kim JM, et al. Molecular characterization of metallo- $\beta$ -lactamase-producing *Acinetobacter baumannii* and *Acinetobacter* genomospecies 3 from Korea: Identification of two new integrons carrying the blaVIM-2 gene cassettes. *J Antimicrob Chemother* 2002;49:837-40.
  56. Beheshti M, Talebi M, Ardebili A, Bahador A, Lari AR. Detection of AdeABC efflux pump genes in tetracycline-resistant *Acinetobacter baumannii* isolates from burn and ventilator-associated pneumonia patients. *J Pharm Bioallied Sci* 2014;6:229-32.
  57. Ranjbar R, Zayeri S, Afshar D. High Frequency of AdeA, AdeB and AdeC Genes among *Acinetobacter baumannii* Isolates. *Iran J Public Health* 2020;49:1539-45.
  58. Nogbou ND, Nkowane GM, Ntshane K, Wairuri CK, Phofa DT, Mokgokong KK, et al. Efflux pump activity and mutations driving multidrug resistance in *Acinetobacter baumannii* at a Tertiary Hospital in Pretoria, South Africa. *Int J Microbiol* 2021;2021:9923816.
  59. Mobasser P, Azimi L, Salehi M, Hosseini F, Fallah F. Multi-drug resistance profiles and expression of AdeIJK and AbeM in *Acinetobacter baumannii* collected from humans by real-time PCR. *J Med Bacteriol* 2018;7:50-6.
  60. Angoti G, Bandehpour M, Goudarzi H, Hajizadeh M, Moghaddam MZ, Kouchaki A. Detection of efflux pump genes (adeA, adeB, adeC and abeM) in *Acinetobacter baumannii* isolated from hospitalized patients, north-west of Iran. *Infect Epidemiol Med* 2016;2:8-11.
  61. AlQumaizi KI, Kumar S, Anwer R, Mustafa S. Differential gene expression of efflux pumps and porins in clinical isolates of MDR *Acinetobacter baumannii*. *Life (Basel)* 2022;12:419.
  62. Rafiei E, Shahini Shams Abadi M, Zamanzad B, Gholipour A. The frequency of efflux pump genes expression in *Acinetobacter baumannii* isolates from pulmonary secretions. *AMB Express* 2022;12:103.
  63. Rajamohan G, Srinivasan VB, Gebreyes WA. Novel role of *Acinetobacter baumannii* RND efflux transporters in mediating decreased susceptibility to biocides. *J Antimicrob Chemother* 2010;65:228-32.
  64. Tahbaz SV, Azimi L, Lari AR. Characterization of aminoglycoside resistance mechanisms in *Acinetobacter baumannii* isolates from burn wound colonization. *Ann Burns Fire Disasters* 2019;30:32:115-21.
  65. Asadollahi K, Taherikalani M, Maleki A, Alizadeh E, Valadbaigi H, Soroush S, et al. Diversity of aminoglycoside modifying enzyme genes among multidrug resistant *Acinetobacter baumannii* genotypes isolated from nosocomial infections in Tehran hospitals and their association with class I integrons. *Acta Microbiol Immunol Hung* 2011;58:359-70.
  66. Kishk R, Soliman N, Nemr N, Eldesouki R, Mahrous N, Gobouri A, et al. Prevalence of aminoglycoside resistance and aminoglycoside modifying enzymes in *Acinetobacter baumannii* among intensive care unit patients, Ismailia, Egypt. *Infect Drug Resist* 2021;14:143-50.
  67. Rashvand P, Peymani A, Mohammadi M, Karami AA, Samimi R, Hajian S, et al. Molecular survey of aminoglycoside-resistant *Acinetobacter baumannii* isolated from tertiary hospitals in Qazvin, Iran. *New Microbes New Infect* 2021;42:100883.
  68. Hammoudi D, Moubareck CA, Hakime N, Houmani M, Barakat A, Najjar Z, et al. Spread of imipenem-resistant *Acinetobacter baumannii* co-expressing OXA-23 and GES-11 carbapenemases in Lebanon. *Int J Infect Dis* 2015;36:56-61.
  69. Ghaith DM, Zafer MM, Al-Agamy MH, Alyamani EJ, Booq RY, Almoazzamy O. The emergence of a novel sequence type of MDR *Acinetobacter baumannii* from the intensive care unit of an Egyptian tertiary care hospital. *Ann Clin Microbiol Antimicrob* 2017;16:34.
  70. Khalilzadegan S, Sade M, Godarzi H, Eslami G, Hallajzade M, Fallah F, et al. Beta-lactamase encoded genes blaTEM and blaCTX among *Acinetobacter baumannii* species isolated from medical devices of intensive care units in Tehran hospitals. *Jundishapur J Microbiol* 2016;9:e14990.
  71. Lowe M, Ehlers MM, Ismail F, Peirano G, Becker PJ, Pitout JDD, et al. *Acinetobacter baumannii*: Epidemiological and beta-lactamase data from two tertiary academic hospitals in Tshwane, South Africa. *Front Microbiol* 2018;9:1280.
  72. Mak JK, Kim MJ, Pham J, Tapsall J, White PA. Antibiotic resistance determinants in nosocomial strains of multidrug-resistant *Acinetobacter baumannii*. *J Antimicrob Chemother* 2009;63:47-54.
  73. Yousefi Nojookambari N, Sadredinamin M, Dehbanipour R, Ghalavand Z, Eslami G, Vaezjalali M, et al. Prevalence of  $\beta$ -lactamase-encoding genes and molecular typing of *Acinetobacter baumannii* isolates carrying carbapenemase OXA-24 in children. *Ann Clin Microbiol Antimicrob* 2021;20:75.
  74. Rynga D, Shariff M, Deb M. Phenotypic and molecular characterization of clinical isolates of *Acinetobacter baumannii* isolated from Delhi, India. *Ann Clin Microbiol Antimicrob* 2015;14:40.
  75. Soltani B, Heidari H, Ebrahim-Saraie HS, Hadi N, Mardaneh J, Motamedifar M. Molecular characteristics of multiple and extensive drug-resistant *Acinetobacter baumannii* isolates obtained from hospitalized patients in Southwestern Iran. *Infez Med* 2018;26:67-76.
  76. Uddin F, McHugh TD, Roulston K, Platt G, Khan TA, Sohail M. Detection of carbapenemases, AmpC and ESBL genes in *Acinetobacter* isolates from ICUs by DNA microarray. *J Microbiol Methods* 2018;155:19-23.
  77. Asaad AM, Ansari S, Ajlan SE, Awad SM. Epidemiology of biofilm producing *Acinetobacter baumannii* nosocomial isolates from a tertiary care hospital in Egypt: A cross-sectional study. *Infect Drug Resist* 2021;14:709-17.
  78. Behdad R, Pargol M, Mirzaie A, Karizi SZ, Noorbazargan H, Akbarzadeh I. Efflux pump inhibitory activity of biologically synthesized

- silver nanoparticles against multidrug-resistant *Acinetobacter baumannii* clinical isolates. *J Basic Microbiol* 2020;60:494-507.
79. Ben RJ, Yang MC, Hsueh JC, Shiang JC, Chien ST. Molecular characterisation of multiple drug-resistant *Acinetobacter baumannii* isolates in southern Taiwan. *Int J Antimicrob Agents* 2011;38:403-8.
  80. Pourhajibagher M, Hashemi FB, Pourakbari B, Aziemzadeh M, Bahador A. Antimicrobial resistance of *Acinetobacter baumannii* to imipenem in Iran: A systematic review and meta-analysis. *Open Microbiol J* 2016;10:32-42.
  81. Eliopoulos GM, Maragakis LL, Perl TM. *Acinetobacter baumannii*: Epidemiology, antimicrobial resistance, and treatment options. *Clin Infect Dis* 2008;46:1254-63.
  82. Manchanda V, Sinha S, Singh NP. Multidrug resistant *Acinetobacter*. *J Global Infect Dis* 2010;2:291-304.
  83. Feizabadi MM, Fathollahzadeh B, Taherikalani M, Rasoolinejad M, Sadeghifard N, Aligholi M, *et al.* Antimicrobial susceptibility patterns and distribution of blaOXA genes among *Acinetobacter* spp. Isolated from patients at Tehran hospitals. *Jpn J Infect Dis* 2008;61:274-8.
  84. Gounden R, Bamford C, van Zyl-Smit R, Cohen K, Maartens G. Safety and effectiveness of colistin compared with tobramycin for multi-drug resistant *Acinetobacter baumannii* infections. *BMC Infect Dis* 2009;9:26.
  85. Ni W, Shao X, Di X, Cui J, Wang R, Liu Y. *In vitro* synergy of polymyxins with other antibiotics for *Acinetobacter baumannii*: A systematic review and meta-analysis. *Int J Antimicrob Agents* 2015;45:8-18.
  86. Vila J, Martí S, Sánchez-Céspedes J. Porins, efflux pumps and multidrug resistance in *Acinetobacter baumannii*. *J Antimicrob Chemother* 2007;59:1210-5.
  87. Hornsey M, Ellington MJ, Doumith M, Thomas CP, Gordon NC, Wareham DW, *et al.* AdeABC-mediated efflux and tigecycline MICs for epidemic clones of *Acinetobacter baumannii*. *J Antimicrob Chemother* 2010;65:1589-93.
  88. Poole K. Efflux-mediated multiresistance in Gram-negative bacteria. *Clin Microbiol Infect* 2004;10:12-26.
  89. Ruzin A, Immermann FW, Bradford PA. RT-PCR and statistical analyses of adeABC expression in clinical isolates of *Acinetobacter calcoaceticus-Acinetobacter baumannii* complex. *Microb Drug Resist* 2010;16:87-9.